Low adiponectin serum level--reduced protective effect on the left ventricular wall thickness

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Syndrome

Background:

• Adiponectin, a fat-secreted hormone, has anti-inflammatory, antiatherosclerotic, and antidiabetic effects.
• Obesity is a significant risk factor for hypertension and cardiovascular diseases.
• The role of adiponectin in left ventricular hypertrophy (LVH) development remains unclear.

Purpose of the Study:

• To investigate if the protective effect of adiponectin against LVH is diminished in overweight, hypertensive patients.
• To assess the relationship between adiponectin levels and LVH in this population.

Main Methods:

• Sixty-one overweight hypertensive patients (BMI 25-30 kg/m²) were divided into four groups based on sex and LVH presence.
• Measurements included glucose, lipids, creatinine clearance, anthropometrics, and cardiac dimensions via two-dimensional ultrasound.
• Serum adiponectin levels were quantified using enzyme immunoassay (ELISA).

Main Results:

• Adiponectin serum levels were significantly lower in hypertensive overweight patients with LVH compared to controls without LVH.
• No significant correlation was found between adiponectin levels and left ventricular wall thickness.
• Hypoadiponectinemia appears to be part of a system contributing to obesity-related hypertension and LVH.

Conclusions:

• Lower adiponectin levels are associated with left ventricular hypertrophy in overweight hypertensive individuals.
• Adiponectin deficiency may play a role in the development of obesity-related hypertension and LVH.
• Further research is needed to elucidate the molecular mechanisms linking adiponectin, obesity, and cardiac remodeling.